Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03ZYQ
|
||||
| Former ID |
DNCL003114
|
||||
| Drug Name |
STX209
|
||||
| Drug Type |
Small molecular drug
|
||||
| Indication | Fragile X syndrome [ICD9: 332, 759.83; ICD10:F02.3, G20, Q99.2] | Phase 3 | [1] | ||
| Company |
Seaside Therapeutics
|
||||
| Formula |
C10H12ClNO2
|
||||
| Canonical SMILES |
C1=CC(=CC=C1C(CC(=O)O)CN)Cl
|
||||
| InChI |
1S/C10H12ClNO2/c11-9-3-1-7(2-4-9)8(6-12)5-10(13)14/h1-4,8H,5-6,12H2,(H,13,14)/t8-/m0/s1
|
||||
| InChIKey |
KPYSYYIEGFHWSV-QMMMGPOBSA-N
|
||||
| PubChem Compound ID | |||||
| PubChem Substance ID |
3153571, 8178796, 11113710, 15121255, 15171983, 34709846, 50066102, 50705527, 90452213, 93625490, 103238751, 103941336, 104345301, 121277848, 123055284, 124490531, 124580859, 126581462, 126616647, 126685003, 126738367, 128418031, 134351756, 135249532, 135649977, 139309014, 143493644, 152032454, 152165673, 152238531, 152258754, 160647599, 160840514, 162009782, 162255234, 163099671, 163405182, 166222624, 170475242, 170485722, 172914818, 175266631, 175270364, 178100431, 186007019, 198993730, 204431203, 208265328, 223518884, 223679055
|
||||
| Target and Pathway | |||||
| Target(s) | Gamma-aminobutyric acid B receptor | Target Info | Modulator | [2] | |
| KEGG Pathway | cAMP signaling pathway | ||||
| Neuroactive ligand-receptor interaction | |||||
| GABAergic synapse | |||||
| Estrogen signaling pathway | |||||
| Morphine addiction | |||||
| Reactome | Activation of G protein gated Potassium channels | ||||
| G alpha (i) signalling events | |||||
| Class C/3 (Metabotropic glutamate/pheromone receptors) | |||||
| Inhibition of voltage gated Ca2+ channels via Gbeta/gamma subunits | |||||
| WikiPathways | GPCRs, Class C Metabotropic glutamate, pheromone | ||||
| Neurotransmitter Receptor Binding And Downstream Transmission In The Postsynaptic Cell | |||||
| Potassium Channels | |||||
| GPCR ligand binding | |||||
| GPCR downstream signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT01706523) Open Label Extension Study of STX209 (Arbaclofen) in Autism Spectrum Disorders. U.S. National Institutes of Health. | ||||
| REF 2 | (http://www.guidetopharmacology.org/) Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 241). | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.